Agreed. It's very tough watching this astonishing record breaking run by the US market, while your money @ Breathtec remains dismally stagnant. Unfortunately, the issues/decisions around Nanose was a failure and raised a glaring red flag that management needed to get it's act together. I truly hope they have now. The realignment to target one specific disease may be helpful to improving investor confidence, but we also need confidence in whomever management chooses as it's next CEO. The biggest concern of all is, when do we ever get to an FDA trial? Management took us to the brink of an FDA trial with Nanose, only to abrupty pull the plug. That was a deep cut to shareholder confidence, and viewed by some as merely a stunt. Moving forward, I do question if any Bullrun portfolio companies will have any involvement with Breathtec in the future. Such as Nash Pharma - currently undertaking private placements with family, friends, and accredited investors. Time will tell. Bring on the news!
/////AMG
News 
Market Data 
Discover 
